Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of TDI01 suspension for moderate to severe chronic graft-versus-host disease
CTR20233772Phase 2Terminated
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TDI01 in chronic graft-versus-host disease (cGVHD), sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Started Mar 2024; status: terminated.
02
Drugs
TDI01
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20233772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233772.